Literature DB >> 23640047

Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.

Jodi A McKenzie1, Tong Liu, Jae Y Jung, Benjamin B Jones, Huseyin A Ekiz, Alana L Welm, Douglas Grossman.   

Abstract

Survivin is an apoptotic and mitotic regulator that is overexpressed in melanoma and a poor prognostic marker in patients with metastatic disease. We recently showed that Survivin enhances melanoma cell motility through Akt-dependent upregulation of α5 integrin. However, the functional role of Survivin in melanoma metastasis is not clearly understood. We found that overexpression of Survivin in LOX and YUSAC2 human melanoma cells increased colony formation in soft agar, and this effect was abrogated by knockdown of α5 integrin by RNA interference. We employed melanoma cell xenografts to determine the in vivo effect of Survivin overexpression on melanoma metastasis. Although Survivin overexpression did not affect primary tumor growth of YUSAC2 or LOX subcutaneous tumors, or indices of proliferation or apoptosis, it significantly increased expression of α5 integrin in the primary tumors and formation of metastatic colonies in the lungs. Additionally, Survivin overexpression resulted in enhanced lung colony formation following intravenous (i.v.) injection of tumor cells in vivo and increased adherence to fibronectin-coated plastic in vitro. Importantly, in vivo inhibition of α5 integrin via intraperitoneal injection of an α5β1 integrin-blocking antibody significantly slowed tumor growth and reduced Survivin-enhanced pulmonary metastasis. Knockdown of α5 integrin in cells prior to i.v. injection also blocked Survivin-enhanced lung colony formation. These findings support a direct role for Survivin in melanoma metastasis, which requires α5 integrin and suggest that inhibitors of α5 integrin may be useful in combating this process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640047      PMCID: PMC3765044          DOI: 10.1093/carcin/bgt155

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  34 in total

Review 1.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

Review 2.  Get a ligand, get a life: integrins, signaling and cell survival.

Authors:  Dwayne G Stupack; David A Cheresh
Journal:  J Cell Sci       Date:  2002-10-01       Impact factor: 5.285

3.  Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer.

Authors:  Xiao-Yuan Chu; Long-Bang Chen; Jing-Hua Wang; Quan-Sheng Su; Ji-Rong Yang; Yong Lin; Li-Jun Xue; Xiao-Bei Liu; Xiao-Bei Mo
Journal:  J Surg Oncol       Date:  2011-11-07       Impact factor: 3.454

Review 4.  Therapy for metastatic melanoma: the past, present, and future.

Authors:  Laura Finn; Svetomir N Markovic; Richard W Joseph
Journal:  BMC Med       Date:  2012-03-02       Impact factor: 8.775

5.  Antisense inhibition of survivin expression as a cancer therapeutic.

Authors:  Rosa A Carrasco; Nancy B Stamm; Eric Marcusson; George Sandusky; Philip Iversen; Bharvin K R Patel
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

6.  Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells.

Authors:  Tong Liu; Brook Brouha; Douglas Grossman
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

7.  Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.

Authors:  Angela Gradilone; Paola Gazzaniga; Diego Ribuffo; Susanna Scarpa; Emanuele Cigna; Fortunata Vasaturo; Ugo Bottoni; Daniele Innocenzi; Stefano Calvieri; Nicolo' Scuderi; Luigi Frati; Anna Maria Aglianò
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

Review 8.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

9.  Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis.

Authors:  A K Mitra; K Sawada; P Tiwari; K Mui; K Gwin; E Lengyel
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

Review 10.  Mechanisms of resistance to RAF inhibitors in melanoma.

Authors:  Andrew E Aplin; Fred M Kaplan; Yongping Shao
Journal:  J Invest Dermatol       Date:  2011-05-19       Impact factor: 8.551

View more
  19 in total

1.  Silencing of ZNF139-siRNA induces apoptosis in human gastric cancer cell line BGC823.

Authors:  Liqiao Fan; Bibo Tan; Yong Li; Qun Zhao; Yü Liu; Dong Wang; Zhidong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.

Authors:  G Renner; H Janouskova; F Noulet; V Koenig; E Guerin; S Bär; J Nuesch; F Rechenmacher; S Neubauer; H Kessler; A-F Blandin; L Choulier; N Etienne-Selloum; M Lehmann; I Lelong-Rebel; S Martin; M Dontenwill
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

3.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  αvβ3 Integrin Mediates Radioresistance of Prostate Cancer Cells through Regulation of Survivin.

Authors:  Tao Wang; Jiayi Huang; Mai Vue; Michael R Alavian; Hira Lal Goel; Dario C Altieri; Lucia R Languino; Thomas J FitzGerald
Journal:  Mol Cancer Res       Date:  2018-09-28       Impact factor: 5.852

5.  Inhibition of Vav3 gene can promote apoptosis of human gastric cancer cell line MGC803 by regulating ERK pathway.

Authors:  Bi-Bo Tan; Ming-Ming Zhang; Yong Li; Qun Zhao; Li-Qiao Fan; Yu Liu; Dong Wang
Journal:  Tumour Biol       Date:  2015-12-22

Review 6.  Survivin - The inconvenient IAP.

Authors:  Dario C Altieri
Journal:  Semin Cell Dev Biol       Date:  2015-01-12       Impact factor: 7.727

7.  Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.

Authors:  Jianglan Liu; Vito W Rebecca; Andrew V Kossenkov; Thomas Connelly; Qin Liu; Alexis Gutierrez; Min Xiao; Ling Li; Gao Zhang; Anastasia Samarkina; Delaine Zayasbazan; Jie Zhang; Chaoran Cheng; Zhi Wei; Gretchen M Alicea; Mizuho Fukunaga-Kalabis; Clemens Krepler; Pedro Aza-Blanc; Chih-Cheng Yang; Bela Delvadia; Cynthia Tong; Ye Huang; Maya Delvadia; Alice S Morias; Katrin Sproesser; Patricia Brafford; Joshua X Wang; Marilda Beqiri; Rajasekharan Somasundaram; Adina Vultur; Denitsa M Hristova; Lawrence W Wu; Yiling Lu; Gordon B Mills; Wei Xu; Giorgos C Karakousis; Xiaowei Xu; Lynn M Schuchter; Tara C Mitchell; Ravi K Amaravadi; Lawrence N Kwong; Dennie T Frederick; Genevieve M Boland; Joseph M Salvino; David W Speicher; Keith T Flaherty; Ze'ev A Ronai; Meenhard Herlyn
Journal:  Cancer Res       Date:  2021-08-30       Impact factor: 13.312

Review 8.  What Inhibits Natural Killers' Performance in Tumour.

Authors:  Ines Papak; Elżbieta Chruściel; Katarzyna Dziubek; Małgorzata Kurkowiak; Zuzanna Urban-Wójciuk; Tomasz Marjański; Witold Rzyman; Natalia Marek-Trzonkowska
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

9.  Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.

Authors:  Nina Oparina; Malin C Erlandsson; Anna Fäldt Beding; Toshima Parris; Khalil Helou; Per Karlsson; Zakaria Einbeigi; Maria I Bokarewa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

10.  IGF-IR promotes prostate cancer growth by stabilizing α5β1 integrin protein levels.

Authors:  Aejaz Sayeed; Carmine Fedele; Marco Trerotola; Kirat K Ganguly; Lucia R Languino
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.